for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evofem Biosciences Inc

EVFM.OQ

Latest Trade

0.82USD

Change

-0.04(-4.13%)

Volume

929,775

Today's Range

0.80

 - 

0.86

52 Week Range

0.75

 - 

5.53

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.86
Open
0.86
Volume
929,775
3M AVG Volume
260.54
Today's High
0.86
Today's Low
0.80
52 Week High
5.53
52 Week Low
0.75
Shares Out (MIL)
150.26
Market Cap (MIL)
129.23
Forward P/E
-0.55
Dividend (Yield %)
--

Next Event

Q2 2021 Evofem Biosciences Inc Earnings Release

Latest Developments

More

Evofem Biosciences Files For Mixed Shelf Of Upto $150 Mln

Evofem Biosciences Reports First Quarter 2021 Financial Results And Provides Corporate Update

Evofem Biosciences Announces Pricing Of $30 Million Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evofem Biosciences Inc

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs). The Company's product, Phexxi vaginal gel, is an on-demand prescription contraceptive gel for women. Its pipeline product candidate, EVO100 vaginal gel, is evaluated for the prevention of chlamydia trachomatis infection and Neisseria gonorrhoeae in women. The Company also focuses on the development of EVO200 vaginal gel, its candidate for the reduction of recurrent bacterial vaginosis (BV).Its subsidiaries include Evofem Biosciences Operations Inc, Evofem Inc and Evofem Ltd.

Industry

Biotechnology & Drugs

Contact Info

12400 High Bluff Dr Ste 600

SAN DIEGO, CA

92130-3077

United States

+1.858.5501900

https://www.evofem.com/

Executive Leadership

William Hall

Non-Executive Independent Chairman of the Board

Saundra L. Pelletier

President, Chief Executive Officer, Director

Justin J. File

Chief Financial Officer

Alexander A. Fitzpatrick

Executive Vice President, General Counsel, Secretary

Russell Barrans

Chief Commercial Officer

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-5.740

2019

-1.990

2020

-2.120

2021(E)

-1.553
Price To Earnings (TTM)
--
Price To Sales (TTM)
83.32
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-1,787.71
Return on Equity (TTM)
-310.36

Latest News

Latest News

BRIEF-Evofem Announces Pricing Of Approximately $100 Million Public Offering Of Common Stock

* EVOFEM ANNOUNCES PRICING OF APPROXIMATELY $100 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Evofem Announces Proposed Public Offering Of Common Stock

* EVOFEM ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

Evofem's gel first non-hormonal contraceptive to get approval in over 30 years

Evofem Biosciences Inc's birth control gel received the U.S. Food and Drug Administration's approval on Friday, making it the first non-hormonal contraceptive for women in over three decades, sending its shares up 3.6%.

Evofem wins U.S. FDA approval for non-hormonal birth control gel

The U.S. Food and Drug Administration on Friday approved Evofem Biosciences Inc's birth control gel, ushering in the first non-hormonal contraceptive for women in over three decades.

BRIEF-Evofem Biosciences Reports First Quarter 2020 Financial Results And Provides Corporate Update

* EVOFEM BIOSCIENCES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Evofem Biosciences Says Three New Phexxi Data Sets Accepted For Presentation

* EVOFEM BIOSCIENCES ANNOUNCES THREE NEW PHEXXI™ DATA SETS ACCEPTED FOR PRESENTATION AT THE 2020 AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS (ACOG) ANNUAL MEETING

BRIEF-Evofem Biosciences Adopts Shareholder Rights Agreement

* EVOFEM BIOSCIENCES ADOPTS SHAREHOLDER RIGHTS AGREEMENT Source text for Eikon: Further company coverage:

BRIEF-Evofem Biosciences Reports Q4 Loss Per Share Of $0.27

* EVOFEM BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Evofem Biosciences Appoints Former FDA Division Director Lisa Rarick To Its Board Of Directors

* EVOFEM BIOSCIENCES APPOINTS FORMER FDA DIVISION DIRECTOR LISA RARICK, M.D., TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Evofem shares surge as contraceptive gel meets late-stage trial goal

Shares of Evofem Biosciences Inc jumped as much as 38 percent on Monday after its birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.

Evofem's hormone-free birth control gel meets main goal in key study

Evofem Biosciences Inc said on Monday its hormone-free birth control gel met the main goal in a late-stage study.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up